Weight Loss

Medications in the Weight Loss category are pharmaceutical products intended to help reduce body weight or support long‑term weight management. They are designed for people identified as overweight or living with obesity, often when lifestyle measures alone—such as changes in diet and physical activity—have not achieved the desired health outcomes. These products vary widely in mechanism, formulation and regulatory status; some are taken short term to support rapid weight loss while others are prescribed for ongoing management of weight as a chronic condition.

Common use cases for weight‑loss medicines include assistance with appetite control, reduction of fat absorption, or alteration of metabolic signals that influence hunger and satiety. Some drugs are used to suppress appetite for short periods, whereas others modify how nutrients are processed or how the central nervous system regulates hunger. Many treatments are part of a broader strategy that includes dietary changes, increased physical activity, and regular monitoring of weight and health markers, and their role can range from intermittent support to sustained therapy for people with higher levels of adiposity or related health risks.

The category contains several distinct types of medications. Lipase inhibitors, represented by active ingredients such as orlistat (sold under names including Xenical in some markets), reduce the amount of dietary fat absorbed in the gut and are available in prescription and over‑the‑counter formulations in varying strengths. Centrally acting combinations, for example formulations combining bupropion and naltrexone (marketed in some regions under the name Contrave), influence appetite and reward pathways in the brain. A newer and increasingly prominent class is GLP‑1 receptor agonists, such as semaglutide, which were originally developed for diabetes but are also used to promote weight loss by slowing gastric emptying and reducing appetite. Stimulant appetite suppressants and other agents with short‑term use are also represented in the broader pharmaceutical landscape for weight management.

How these medicines are administered and monitored differs by agent. Some are oral tablets taken with meals, while others are injectable and given on a weekly or daily schedule. Dosing regimens may start low and increase according to tolerability and clinical protocols in order to balance effectiveness with side effects. The duration of treatment can range from a few weeks to long‑term use, depending on the medication’s approved indications, clinical goals, and individual response. Products that modify nutrient absorption often require attention to diet composition, and certain therapeutic classes have distinct administration considerations tied to timing or concomitant medications.

Safety considerations are an important aspect of this category because different drugs carry different side effect profiles and contraindications. Gastrointestinal effects such as oily stools, flatulence or loose bowel movements are commonly reported with fat‑absorption inhibitors. Appetite‑modulating agents can cause nausea, headache, dizziness or mood changes in some people; central nervous system–active medications may have additional warnings relating to psychiatric or cardiovascular effects. Several weight‑loss medicines are not recommended during pregnancy or breastfeeding, and some have specific interactions with other medications. Monitoring for adverse effects and reviewing medical history, current medications and comorbid conditions are typical components of safe use.

When selecting a weight‑loss medicine, consumers typically consider the expected effectiveness, side‑effect profile, route of administration (oral versus injectable), treatment duration, contraindications and how well the medication fits into daily life. Accessibility, such as whether a product requires a prescription, and regulatory approvals for specific indications also influence choice. Both clinical goals—such as modest weight reduction versus substantial long‑term management—and personal preferences shape which option people explore, and well‑known examples that illustrate the range of approaches include orlistat (Xenical), the bupropion/naltrexone combination (Contrave) and GLP‑1 receptor agonists like semaglutide.